Hair loss treatment market is estimated to be valued at USD 4.78 Bn in 2025 and is expected to reach USD 7.28 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032.
The global hair loss treatment market growth is powered by growing awareness of physical looks, rising stress levels, hormonal imbalances, and genetic vulnerabilities. An expanding aging population, combined with lifestyle changes and greater disposable incomes, is boosting demand for pharmaceutical as well as cosmetic solutions to treat hair loss. Patients are increasingly opting for non-surgical, effective treatments—anything from topical creams and oral drugs to hair transplant surgeries and regenerative medicines. In 2024, technological advancements such as the use of follicular-targeted nanocarriers and commercialization of medicines such as ritlecitinib and pyrilutamide have broadened therapies.
|
Current Events |
Description and its impact |
|
Advances in pharmaceutical treatments for alopecia areata |
|
|
Introduction of Pyrilutamide as a Topical Treatment |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Increasing prevalence of diseases such as telogen effluvium, androgenetic alopecia, alopecia areata, and others is expected to boost demand for hair loss treatment, thus, propelling the market growth over the forecast period. In 2024, Merck received FDA clearance for a novel oral therapy targeting androgenetic alopecia, reflecting the industry's commitment to developing effective treatments.
Key market players are focusing on adoption of research and development activities for treatment of hair loss diseases such as alopecia areata, and this is expected to drive the market growth over the forecast period. For instance, Concert Pharmaceuticals, a subsidiary of Sun Pharmaceutical Industries Pvt. Ltd., an India-based global pharmaceutical company, has its drug candidate CTP-543 is in phase-III of clinical trial. The CTP-543 is been tested for a treatment solution for alopecia areata.
Key market players are focusing on research and development activities for development of treatment solution for hair loss diseases such as non-cicatricial, telogen effluvium, androgenetic alopecia, and others. This is expected to drive the market growth over the forecast period. For instance, Aclaris Therapeutics, Inc., an U.S.-based clinical-stage biopharmaceutical company, has its drug candidate named ATI-50002 is in phase-II of clinical trial, is been tested as a potential treatment option for androgenetic alopecia.
By product type, the market is segmented into corticosteroids, antihypertensive, topical immune-modulators, and others. Out of which, the topical Immune-modulators segment is expected to hold a dominant position in the global hair loss treatment market during the forecast period due to increasing product launch and approval by key market players.
By product type, the market is segmented into, Noncicatricial, Cicatricial, and others. Out of which, the Noncicatricial segment is expected to hold a dominant position in the global hair loss treatment market during the forecast period due to its higher prevalence and broader treatment options compared to cicatricial alopecia.
By route of administration, the market is segmented into oral and topical. Out of which, the oral segment is expected to dominate the market over the forecast period due to ease of administration of oral dosage form and increasing product approval by regulatory authorities.
By gender, the market is segmented into male and female. Out of which, the male segment is expected to dominate the market over the forecast period due to high prevalence of androgenic hair loss in males.
By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period due to increasing number of hospitals and hospital pharmacies.
To learn more about this report, Download Free Sample
Among region, North America is estimated to hold a dominant position in the global hair loss treatment market over the forecast period. North America is estimated to hold 33.5% of the market share in 2025 due to presence of major players such as Cipla Inc., Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc, and others in North America.
The U.S. is still the leading market in the global hair loss treatment market, with about 32% market share in 2023. This is fueled by a high incidence of hair loss, well-developed healthcare infrastructure, and a high demand for both surgical and non-surgical treatments. The market is expected to keep expanding at a CAGR of 7.2% up to 2035, driven by innovation and a huge consumer base in need of effective treatments.
Germany dominates the European market, with the highest revenue share in 2025. The nation enjoys a high prevalence of hair loss, a robust healthcare infrastructure, and a high demand for natural and organic treatment methods. Germany will have a CAGR of 6.9% during 2035, boosted by rising awareness and ease of access to sophisticated therapies.
China is the biggest market in Asia, with a population of more than 250 million experiencing hair loss. The market is growing at a fast pace because of urbanization, increased disposable incomes, and a decrease in the stigma associated with hair treatments. The increased e-commerce segment and growing consumer knowledge are also driving the market growth.
India's market for treating hair loss is growing strongly, with an estimated CAGR of 6.5% up to 2035. This growth is driven by urbanization, changing lifestyles, and the use of natural and Ayurvedic products. These are also fueled by the growing middle class and heightened awareness for hair health.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.2% | 2032 Value Projection: | USD 7.28 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Viviscal, Cipla Inc., Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Reddy’s Laboratories, Ranbaxy Laboratories Ltd., HCell Inc., Follica, Inc., Aurobindo Pharma, and Zydus Lifesciences Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The hair loss treatment market is being propelled by shifting consumer needs and advancements in therapeutic innovations. A key driver is the rising prevalence of hair loss conditions like androgenetic alopecia and alopecia areata, attributed to lifestyle changes, hormonal imbalances, and stress among younger demographics. Increased awareness through advocacy groups and digital platforms has reduced stigma, encouraging earlier intervention. However, market growth faces restraints such as regulatory hurdles for novel therapies and patient skepticism toward long-term efficacy of topical treatments like minoxidil, despite its mainstream adoption.]. High costs associated with advanced procedures also limit accessibility in emerging economies.
Opportunities lie in personalized treatment approaches leveraging genetic profiling and non-invasive technologies such as low-level laser therapy and platelet-rich plasma (PRP) injections, which offer reduced side effects and improved patient outcomes. The North America region is emerging as a high-growth area due to rising disposable incomes, cultural emphasis on haircare, and expanding online retail channels for specialized products. Meanwhile, Asia Pacific maintains dominance through robust R&D investments and early adoption of innovations like anti-aging haircare formulations and AI-driven diagnostic tools.
Manufacturers are increasingly focusing on natural ingredient-based solutions and gender-specific formulations to address diverse consumer needs. Strategic collaborations between biotech firms and cosmetic giants are expected to bridge gaps between medical efficacy and aesthetic appeal, positioning the market for sustained evolution despite existing challenges.
Definition: Alopecia is a type of hair loss caused due to specific medical conditions or dietary problems. Sedentary lifestyles and poor eating habits of individuals increases hair loss. Aging, hormonal imbalance, and increasing chronic diseases like cancer, hypertension, arthritis, and depression, particularly in the middle-aged population, all contribute to hair loss.
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
